Clin2
NCT06548490Possibly a fitRecruiting

Semaglutide for Opioid Use Disorder

Opioid Use DisorderOpioid Abuse and AddictionNarcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisorderOpioid

Treatments studied

Part of Mental health clinical trials.

This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old
  • You have been diagnosed with moderate to severe opioid use disorder and are in outpatient treatment
  • You have been on buprenorphine for at least 2 weeks or methadone for at least 4 weeks and still have had opioid use
  • You are not pregnant, breastfeeding, or planning pregnancy and agree to use birth control if needed
  • You do not have certain medical conditions like type 1 diabetes, severe heart disease, pancreatitis, thyroid cancer, or kidney failure

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06639464Recruiting· Phase 2
Semaglutide to help with opioid recovery

This trial tests if semaglutide, a medicine sometimes used for weight management, can help people recovering from opioid use disorder stay on track. It is for adults who have already started buprenorphine treatment and are ready to take part in a research study.

Boston, Massachusetts
NCT06691243Recruiting· Phase 2
Testing semaglutide for cocaine use in adults

This study tests if the diabetes drug semaglutide (also used for weight loss) can help reduce cocaine use in adults, including those living with HIV. It's free and lasts about 8 weeks.

Washington D.C., District of Columbia
NCT07509112Not yet recruiting· Phase 2
Semaglutide for treating methamphetamine use disorder

This trial tests if semaglutide, a medication that affects appetite and cravings, can help people reduce or stop using methamphetamine. It may be a new option for those struggling with moderate to severe methamphetamine use disorder.

Darlinghurst, New South Wales
NCT07627074Recruiting
Real-world weight loss study with semaglutide

This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.

Seattle, Washington
NCT07227948Recruiting· Phase 2
Testing semaglutide for cocaine use disorder

This study tests whether semaglutide, a medication used for weight management, can help reduce cocaine use in people with cocaine use disorder. You may qualify if you have a body mass index (BMI) of 25 or higher and recently used cocaine.

Houston, Texas
NCT07513168Recruiting· Phase 4
Low-dose semaglutide for weight loss in obese adults

This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.

Hyderābād, Sindh

Hear when a new Opioid Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.